熱門資訊> 正文
Oramed Pharmaceuticals GAAP每股收益为1.26美元
2025-11-17 22:14
- Oramed Pharmaceuticals press release (ORMP): nine-month period 2025 GAAP EPS of $1.26.
- Robust balance sheet growth: Total assets increased 42% from $155.3 million to $220.5 million year-over-year.
- Operating expenses: R&D expenses decreased from $4.9 million to $4.4 million; G&A expenses increased from $4.3 million to $5.0 million.
More on Oramed Pharmaceuticals
- Seeking Alpha’s Quant Rating on Oramed Pharmaceuticals
- Historical earnings data for Oramed Pharmaceuticals
- Financial information for Oramed Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
